Retatrutide (also called LY3437943) is a next-generation triple hormone receptor agonist developed by Eli Lilly.
It activates GLP-1, GIP, and glucagon receptors simultaneously.
It is being studied as a once-weekly injectable therapy for obesity, type 2 diabetes, and related metabolic conditions.
As of 2025, it is still investigational (not FDA-approved).
GLP-1 receptor agonism → reduces appetite, slows gastric emptying, improves insulin secretion.
GIP receptor agonism → enhances insulin response, may reduce GI side effects of GLP-1s.
Glucagon receptor agonism → increases energy expenditure and reduces liver fat.
Together, this triple action targets both caloric intake (less hunger) and energy expenditure (more fat burning).
Participants lost:
–7.2% at 1 mg/week
–22–24% at 8–12 mg/week
Some individuals lost over 25% of body weight, which is greater than results seen with semaglutide (Wegovy) or tirzepatide (Zepbound).
Showed robust glucose lowering and significant weight loss.
Early data suggests it may help reduce liver fat (NAFLD/NASH) as well.
Mostly gastrointestinal (similar to semaglutide/tirzepatide):
Nausea, vomiting, diarrhea, constipation
Other possible issues: decreased appetite, fatigue, mild dizziness
Serious risks (still under study): gallbladder disease, pancreatitis, rare GI obstruction
Contraindications will likely mirror other incretin drugs (e.g., personal/family history of medullary thyroid carcinoma or MEN2).
Retatrutide = triple agonist (GLP-1 + GIP + glucagon), investigational for obesity and diabetes.
Efficacy: Early studies show up to 24% weight loss in 48 weeks, the most potent seen so far in this drug class.
Dosing: Weekly injections, titrated gradually (1 mg → 12 mg).
Status: Not FDA-approved yet (likely timeline ~2026–2027 if trials remain positive).
Potential: May outperform both semaglutide and tirzepatide in weight loss and metabolic improvement.
Retatrutide (also called LY3437943) is a next-generation triple hormone receptor agonist developed by Eli Lilly.
It activates GLP-1, GIP, and glucagon receptors simultaneously.
It is being studied as a once-weekly injectable therapy for obesity, type 2 diabetes, and related metabolic conditions.
As of 2025, it is still investigational (not FDA-approved).
GLP-1 receptor agonism → reduces appetite, slows gastric emptying, improves insulin secretion.
GIP receptor agonism → enhances insulin response, may reduce GI side effects of GLP-1s.
Glucagon receptor agonism → increases energy expenditure and reduces liver fat.
Together, this triple action targets both caloric intake (less hunger) and energy expenditure (more fat burning).
Participants lost:
–7.2% at 1 mg/week
–22–24% at 8–12 mg/week
Some individuals lost over 25% of body weight, which is greater than results seen with semaglutide (Wegovy) or tirzepatide (Zepbound).
Showed robust glucose lowering and significant weight loss.
Early data suggests it may help reduce liver fat (NAFLD/NASH) as well.
Mostly gastrointestinal (similar to semaglutide/tirzepatide):
Nausea, vomiting, diarrhea, constipation
Other possible issues: decreased appetite, fatigue, mild dizziness
Serious risks (still under study): gallbladder disease, pancreatitis, rare GI obstruction
Contraindications will likely mirror other incretin drugs (e.g., personal/family history of medullary thyroid carcinoma or MEN2).
Retatrutide = triple agonist (GLP-1 + GIP + glucagon), investigational for obesity and diabetes.
Efficacy: Early studies show up to 24% weight loss in 48 weeks, the most potent seen so far in this drug class.
Dosing: Weekly injections, titrated gradually (1 mg → 12 mg).
Status: Not FDA-approved yet (likely timeline ~2026–2027 if trials remain positive).
Potential: May outperform both semaglutide and tirzepatide in weight loss and metabolic improvement.
